Pasar al contenido principal

MECANISMOS REGULADORES Y FUNCION DE LAS FOSFATASAS DE ESPECIFICIDAD DUAL EN LA RESPUESTA INMUNOLOGICA DE LOS LINFOCITOS T

SAF2016-75656-P

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Phosphatase of regenerating liver-1 (PRL-1) regulates actin dynamics during immunological synapse assembly and t cell effector function

  • Castro-Sánchez, Patricia
  • Reyes, Raquel
  • Cabañas, Carlos
  • Roda-Navarro, Pedro
The regulatory role of most dual specific phosphatases during T cell activation remains unknown. Here, we have studied the expression and function of phosphatases of regenerating liver (PRLs: PRL-1, PRL-2, and PRL-3) during T cell activation, as well as, the dynamic delivery of PRL-1 to the Immunological Synapse (IS). We found that T cell activation downregulates the expression of PRL-2, resulting in an increased PRL-1/PRL-2 ratio. PRL-1 redistributed at the IS in two stages: Initially, it was transiently accumulated at scanning membranes enriched in CD3 and actin, and at later times, it was delivered at the contact site from pericentriolar, CD3∂-containing, vesicles. Once at the established IS, PRL-1 distributed to LFA-1 and CD3ϵ sites. Remarkably, PRL-1 was found to regulate actin dynamics during IS assembly and the secretion of IL-2. Moreover, pharmacological inhibition of the catalytic activity of the three PRLs reduced the secretion of IL-2. These results provide evidence indicating a regulatory role of PRL-1 during IS assembly and highlight the involvement of PRLs in immune responses by mature T cells., Ministry of Economy and Competitiveness (MINECO) with research grants SAF2012-33218 and SAF2016-75656-P. The later from the Agencia Estatal de investigación cofounded by “fondo Europeo de desarrollo regional (FEDER)
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers

  • Blanco, Belén
  • Ramírez-Fernández, Ángel
  • Bueno, Clara|||0000-0003-1442-6216
  • Argemí-Muntadas, Lidia
  • Fuentes, Patricia
  • Aguilar-Sopeña, Óscar
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Tapia-Galisteo, Antonio
  • Díez-Alonso, Laura
  • Segura-Tudela, Alejandro
  • Castellà, Maria
  • Marzal, Berta
  • Betriu-Méndez, Sergi|||0000-0002-4199-1168
  • Harwood, Seandean L.
  • Compte, Marta
  • Lykkemark, Simon
  • Erce-Llamazares, Ainhoa
  • Rubio-Pérez, Laura
  • Jiménez-Reinoso, Anaïs
  • Domínguez-Alonso, Carmen
  • Neves, Maria
  • Morales, Pablo
  • Paz-Artal, Estela|||0000-0002-0646-2375
  • Guedan, Sonia|||0000-0002-9605-0760
  • Sanz, Laura
  • Toribio, Maria L.
  • Roda-Navarro, Pedro
  • Juan, Manel|||0000-0002-3064-1648
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Álvarez-Vallina, Luis
Chimeric antigen receptor (CAR)-modified T cells have revolutionized the treatment of CD19-positive hematologic malignancies. Although anti-CD19 CAR-engineered autologous T cells can induce remission in patients with B-cell acute lymphoblastic leukemia, a large subset relapse, most of them with CD19-positive disease. Therefore, new therapeutic strategies are clearly needed. Here, we report a comprehensive study comparing engineered T cells either expressing a second-generation anti-CD19 CAR (CART19) or secreting a CD19/CD3-targeting bispecific T-cell engager antibody (STAb-T19). We found that STAb-T19 cells are more effective than CAR-T19 cells at inducing cytotoxicity, avoiding leukemia escape in vitro, and preventing relapse in vivo. We observed that leukemia escape in vitro is associated with rapid and drastic CAR-induced internalization of CD19 that is coupled with lysosome-mediated degradation, leading to the emergence of transiently CD19-negative leukemic cells that evade the immune response of engineered CAR-T19 cells. In contrast, engineered STAb-T19 cells induce the formation of canonical immunologic synapses and prevent the CD19 downmodulation observed in anti- CD19 CAR-mediated interactions. Although both strategies show similar efficacy in short-term mouse models, there is a significant difference in a long-term patient-derived xenograft mouse model, where STAb-T19 cells efficiently eradicated leukemia cells, but leukemia relapsed after CAR-T19 therapy. Our findings suggest that the absence of CD19 downmodulation in the STAb-T19 strategy, coupled with the continued antibody secretion, allows an efficient recruitment of the endogenous T-cell pool, resulting in fast and effective elimination of cancer cells that may prevent CD19-positive relapses frequently associated with CAR-T19 therapies.